advertisement
Abstract #6683 Published in IGR 4-1
Effects of topical administration of 0.005% latanoprost solution on eyes of clinically normal horses
Willis AM; Diehl KA; Hoshaw Woodard S; Kobayashi I; Vitucci MP; Schmall LMAmerican Journal of Veterinary Research 2001; 62: 1945-1951
OBJECTIVE: To determine the effect of 0.005% latanoprost solution on intraocular pressure (IOP) of eyes of clinically normal horses and establish the frequency of adverse effects of drug administration. ANIMALS: Twenty adult clinically normal horses. PROCEDURE: IOP was recorded (7, 9, and 11 a.m.; 3, 5, and 7 p.m.) on days 1 and 2 (baseline), days 3 to 7 (treatment), and days 8 to 9 (follow-up). Latanoprost was administered to one randomly assigned eye of each horse every 24 hours during the treatment period, following the 7-a.m. IOP recording. Pupil size and the presence or absence of conjunctival hyperemia, epiphora, blepharospasm, blepharedema, and aqueous flare were recorded prior to IOP measurement. RESULTS: IOP was reduced from baseline by a mean value of 1.03 mmHg (5%) in males and 3.01 mmHg (17%) in females during the treatment period. Miosis developed in all treated eyes and was moderate to marked in 77% of horses, with the peak effect observed four to eight hours after drug administration. Conjunctival hyperemia, epiphora, blepharospasm, and blepharedema were present in 100, 57, 42, and 12% of treated eyes, respectively, two to 24 hours following drug administration. Aqueous flare was not observed at any time point. CONCLUSIONS AND CLINICAL RELEVANCE: Although IOP was reduced with every 24-hour dosing of latanoprost, the frequency of prostaglandin-induced adverse events was high. Because recurrent uveitis appears to be a risk factor for glaucoma in horses, topical administration of latanoprost may potentiate prostaglandin-mediated inflammatory disease in affected horses.
Dr. A.M. Willis, Rowley Memorial Animal Hospital, 171 Union Street, Springfield, MA 01105, USA
Classification:
5 Experimental glaucoma; animal models
11.4 Prostaglandins (Part of: 11 Medical treatment)
